Prospect: information for the user
Bimzelx320mg solution for injection in a pre-filled syringe
bimekizumab
This medicine is subject to additional monitoring, which will speed up the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section4includes information on how to report these adverse effects.
Read this prospect carefully before starting to use this medicine, because it contains important information for you.
1.What is Bimzelx and what it is used for
2.What you need to know before starting to use Bimzelx
3.How to use Bimzelx
4.Possible adverse effects
5.Storage of Bimzelx
6.Contents of the package and additional information
Instructions for use
What is Bimzelx
Bimzelx contains the active ingredient bimekizumab.
What Bimzelx is used for
Bimzelx is used to treat the following inflammatory diseases:
Plaque psoriasis
Bimzelx is used in adults to treat a skin disorder called plaque psoriasis. Bimzelx reduces symptoms, including pain, itching, and skin peeling.
Psoriatic arthritis
Bimzelx is used to treat adults with psoriatic arthritis. Psoriatic arthritis is a disease that causes inflammation of the joints, often accompanied by plaque psoriasis. If you have active psoriatic arthritis, you may have been given other medications first. If these medications do not work well enough or if you are intolerant, you will receive Bimzelx alone or in combination with another medication called methotrexate.
Bimzelx reduces inflammation and can help reduce joint pain, stiffness, swelling in the joints and around them, psoriatic skin rash, and psoriatic nail damage, as well as slow down cartilage and bone damage in the affected joints. These effects help control the signs and symptoms of the disease, make it easier to perform your daily activities, reduce fatigue, and improve your quality of life.
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis)
Bimzelx is used to treat adults with an inflammatory disease that mainly affects the spine and causes inflammation of the spine joints, called axial spondyloarthritis. If the condition is not visible on X-rays, it is called “non-radiographic axial spondyloarthritis”; if it occurs in patients with visible signs on X-rays, it is called “ankylosing spondylitis” or “radiographic axial spondyloarthritis”.
If you have axial spondyloarthritis, you will first be given other medications. If you do not respond well enough to these medications, you will be given Bimzelx to reduce the signs and symptoms of the disease, decrease inflammation, and improve your physical functional capacity. Bimzelx can help reduce back pain, stiffness, and fatigue, making it easier to perform your daily activities and improving your quality of life.
Hidradenitis supurativa
Bimzelx is used in adults to treat a disease called hidradenitis supurativa (sometimes called inverse acne or Verneuil's disease). Hidradenitis supurativa is a chronic inflammatory skin disease that causes painful lesions in the form of nodules (bumps) and abscesses (boils), as well as lesions that can suppurate pus. It mainly affects specific areas of the skin, such as under the breasts, armpits, the inner thighs, groin, and buttocks. In the affected areas, scars can also form. You will first be given other medications. If your response to these medications is not sufficient, you will be given Bimzelx.
Bimzelx reduces inflammatory nodules (bumps), abscesses (boils), and lesions that can suppurate pus, as well as the pain caused by hidradenitis supurativa.
How Bimzelx works
Bimekizumab, the active ingredient in Bimzelx, belongs to a group of medications called interleukin inhibitors (IL). Bimekizumab acts by reducing the activity of two interleukins called IL-17A and IL-17F, which are involved in the production of inflammation. The levels of these interleukins are elevated in inflammatory diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis supurativa.
Do not use Bimzelx
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to use Bimzelx if:
Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Stop using Bimzelx and inform your doctor or seek medical assistance immediately if you observe blood in your stools, abdominal cramps, pain, diarrhea, or weight loss. These may be signs of the onset or worsening of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
Be aware of the appearance of infections and allergic reactions
In rare cases, Bimzelx may cause severe infections. Talk to your doctor or seek medical assistanceimmediatelyif you observe any signs of severe infection. These signs are listed in “Severe adverse reactions” in section4.
Bimzelx may cause severe allergic reactions. Talk to your doctor or seek medical assistanceimmediatelyif you observe any signs of severe allergic reaction. These signs may include:
Children and adolescents
This medication should not be administered to children and adolescents under18years of age, as it has not been studied in this age group.
Other medications and Bimzelx
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. It is preferable to avoid using Bimzelx during pregnancy, as it is not known how this medication may affect the baby.
If you are a woman and may become pregnant, you should use contraception while using this medication and for at least17weeks after the last dose of Bimzelx.
If you are breastfeeding or plan to breastfeed, consult your doctor before using this medication. You and your doctor should decide whether you can breastfeed or use Bimzelx.
Driving and operating machinery
It is unlikely that Bimzelx will affect your ability to drive and operate machinery.
Bimzelxcontainspolisorbate 80
This medication contains 0.4mg of polisorbate 80 per ml of solution. Polisorbates may cause allergic reactions. Inform your doctor if you have any known allergies.
Bimzelx contains sodium
This medication contains less than1mmol (23mg) of sodium per dose; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
How much Bimzelx is administered and for how long
Plaque psoriasis
The recommended dose, administered in the form of a subcutaneous injection, is as follows:
Psoriatic arthritis
The recommended dose, administered in the form of a subcutaneous injection, is as follows:
Axial spondyloarthritis, including non-radiographic axial spondyloarthritis and ankylosing spondylitis (radiographic axial spondyloarthritis)
The recommended dose, administered via a subcutaneous injection, is as follows:
Hidradenitis supurativa
The recommended dose, administered in the form of a subcutaneous injection, is as follows:
You and your doctor or nurse will decide whether to inject this medication yourself. Do not inject this medication unless a healthcare professional has taught you how to do it. A caregiver can also administer the injections if they have been taught how to do it.
Read the“Instructions for use” at the end of this leaflet before injecting the pre-filled syringe of Bimzelx 320 mg injectable yourself.
If you use more Bimzelx than you should
Inform your doctor if you have used more Bimzelx than you should or if you have injected the dose too early.
If you forget to use Bimzelx
Talk to your doctor if you have forgotten to inject a dose of Bimzelx.
If you interrupt treatment with Bimzelx
Talk to your doctor before stopping the use of Bimzelx. If you stop treatment, symptoms may reappear.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Severe side effects
Inform your doctor or seek medical assistanceimmediatelyif you experience any of the following severe side effects:
Severe infection- symptoms may include:
Your doctor will decide if you can continue using Bimzelx.
Other side effects
Inform your doctor, pharmacist, or nurse if you experience any of the following side effects:
Very common(may affect more than1person in every10)
Common(may affect up to1person in every10people)
Rare(may affect up to1person in every100people)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet. You can also report them directly through thenationalreporting system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and on the packaging after EXP/CAD. The expiration date is the last day of the month indicated.
Store in the refrigerator between2°C and8°C. Do not freeze.
Store the preloaded pens in the original box to protect them from light.
Bimzelx can be stored outside the refrigerator for a maximum of25days. It must be stored in the outer packaging, at no more than25°C and away from direct light. Do not use the preloaded pens after this period of time. There is a space in the box for you to write the date when you took it out of the refrigerator.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the packaging and the medication that you no longer need. This will help protect the environment.
Composition of Bimzelx
Appearance of Bimzelx and contents of the pack
Bimzelx is a transparent to slightly opalescent liquid. The color may vary from colorless to light yellowish-brown. It comes in a single-use disposable pre-filled pen.
Bimzelx 320mg injectable solution in pre-filled pen is available in packs containing1pre-filled pen and in multiple packs of3boxes, each containing1pre-filled pen
Only some pack sizes may be marketed.
Marketing Authorization Holder
UCB Pharma S.A.
Allée de la Recherche60
B-1070Brussels, Belgium
Responsible for manufacturing
UCB Pharma S.A.
Chemin du Foriest
B-1420Braine-l’Alleud, Belgium
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien UCB Pharma S.A./NV Tel/Tel: +32/ (0)25599200 | Lithuania UCB Pharma Oy Finland Tel: +358925144221(Finland) | |
???? ? ?? ?? ???????? ???? Te?.: +359(0)29623049 | Luxembourg/Luxemburg UCB Pharma S.A./NV Tél/Tel: +32/ (0)25599200 (Belgium/Belgien) | |
Czech Republic UCB s.r.o. Tel: +420221773411 | Hungary UCB Magyarország Kft. Tel.: +36-(1)3910060 | |
Denmark UCB Nordic A/S Tlf.: +45/32462400 | Malta Pharmasud Ltd. Tel: +356/21376436 | |
Germany UCB Pharma GmbH Tel: +49/ (0)2173484848 | Netherlands UCB Pharma B.V. Tel: +31/ (0)76-5731140 | |
Estonia UCB Pharma Oy Finland Tel: +358925144221(Finland) | Norway UCB Nordic A/S Tlf: +47/67 16 5880 | |
Greece UCBΑ.Ε. Τηλ: +30/2109974000 | Austria UCB Pharma GmbH Tel: +43-(0)12918000 | |
Spain UCB Pharma, S.A. Tel: +34/915703444 | Poland UCB Pharma Sp. z o.o./VEDIM Sp. z o.o. Tel.: +48226969920 | |
France UCB Pharma S.A. Tél: +33/(0)147294435 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: +351 21 302 5300 | |
Croatia Medis Adria d.o.o. Tel: +385(0)12303446 Ireland UCB (Pharma) Ireland Ltd. Tel: +353/ (0)1-4637395 | Romania UCB Pharma Romania S.R.L. Tel: +40213002904 Slovenia Medis, d.o.o. Tel: +38615896900 | |
Iceland Vistor hf. Sími: +3545357000 | Slovakia UCB s.r.o., organisational unit Tel: +421(0)259202020 | |
Italy UCB Pharma S.p.A. Tel: +39/02300791 | Finland UCB Pharma Oy Finland Puh/Tel: +358925144221 | |
Cyprus Lifepharma (Z.A.M.) Ltd Τηλ: +35722056300 | Sweden UCB Nordic A/S Tel: +46/ (0)40294 900 | |
Lithuania UCB Pharma Oy Finland Tel: +358925144221(Finland) | ||
Last update of this leaflet:
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency: https://www.ema.europa.eu
Instructions for use
Read the following instructions carefully before using the Bimzelx 320mg pre-filled pen.
Bimzelx 320mg pre-filled pen at a glance (see figureA):
Important information:
Do not use this medicine and return it to the pharmacy if:
For a more comfortable injection:Take the 320mg pre-filled pen out of the refrigerator and leave it on a flat surface at room temperature in its original packaging for30-45minutesbefore injection.
Follow the steps below each time you use Bimzelx.
Step1: Preparation of the injection
Place the following items on a clean, flat, and well-lit work surface, such as a table:
You will also need (not included in the pack):
Step2: Choose the injection site and prepare the injection
2a: Choose the injection site
2b: Wash your hands thoroughly with soap and water and dry them with a clean, dry towel
2c: Prepare the skin
2d: Check the pre-filled pen (see figureD)
Step3: Inject Bimzelx
3a: Remove the cap from the pre-filled pen
3b: Hold the pre-filled pen at a90degree angle to the cleaned skin site (see figureF)
3c: Place the pre-filled pen flat against the skin and then press the pre-filled pen firmly against the skin
You will hear a click. The injection starts when you hear the first “click” (see figureG).
3d: Hold the pre-filled pen in place and press it firmly against the skin. It will take approximately20seconds to receive the full dose.
3e: Remove the pre-filled pen by pulling it out carefully. The needle guard will automatically cover the needle
Step4: Dispose of the used Bimzelx pre-filled pen
Place the used pre-filled pen in a sharps disposal container immediately after use (see figureJ).
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.